Robert E Bristow1, Jenny Chang2, Argyrios Ziogas2, Belinda Campos3, Leo R Chavez3, Hoda Anton-Culver2. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine - School of Medicine, Irvine, CA. Electronic address: rbristow@uci.edu. 2. Department of Epidemiology, University of California, Irvine - School of Medicine, Irvine, CA. 3. University of California, Irvine - School of Social Sciences, Irvine, CA.
Abstract
BACKGROUND: The regional impact of care at a National Cancer Institute Comprehensive Cancer Center (NCI-CCC) on adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines and survival is unclear. STUDY DESIGN: We performed a retrospective population-based study of consecutive patients diagnosed with epithelial ovarian cancer between January 1, 1996 and December 31, 2006 in southern California. Patients were stratified according to care at an NCI-CCC (n = 5), non-NCI high-volume hospital (≥ 10 cases/year, HVH, n = 29), or low-volume hospital (<10 cases/year, LVH, n = 158). Multivariable logistic regression and Cox-proportional hazards models were used to examine the effect of NCI-CCC status on treatment guideline adherence and ovarian cancer-specific survival. RESULTS: A total of 9,933 patients were identified (stage I, 22.8%; stage II, 7.9%; stage III, 45.1%; stage IV, 24.2%), and 8.1% of patients were treated at NCI-CCCs. Overall, 35.7% of patients received NCCN guideline adherent care, and NCI-CCC status (odds ratio [OR] 1.00) was an independent predictor of adherence to treatment guidelines compared with HVHs (OR 0.83, 95% CI 0.70 to 0.99) and LVHs (OR 0.56, 95% CI 0.47 to 0.67). The median ovarian cancer-specific survivals according to hospital type were: NCI-CCC 77.9 (95% CI 61.4 to 92.9) months, HVH 51.9 (95% CI 49.2 to 55.7) months, and LVH 43.4 (95% CI 39.9 to 47.2) months (p < 0.0001). National Cancer Institute Comprehensive Cancer Center status (hazard ratio [HR] 1.00) was a statistically significant and independent predictor of improved survival compared with HVH (HR 1.18, 95% CI 1.04 to 1.33) and LVH (HR 1.30, 95% CI 1.15 to 1.47). CONCLUSIONS: National Cancer Institute Comprehensive Cancer Center status is an independent predictor of adherence to ovarian cancer treatment guidelines and improved ovarian cancer-specific survival. These data validate NCI-CCC status as a structural health care characteristic correlated with superior ovarian cancer quality measure performance. Increased access to NCI-CCCs through regional concentration of care may be a mechanism to improve clinical outcomes.
BACKGROUND: The regional impact of care at a National Cancer Institute Comprehensive Cancer Center (NCI-CCC) on adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines and survival is unclear. STUDY DESIGN: We performed a retrospective population-based study of consecutive patients diagnosed with epithelial ovarian cancer between January 1, 1996 and December 31, 2006 in southern California. Patients were stratified according to care at an NCI-CCC (n = 5), non-NCI high-volume hospital (≥ 10 cases/year, HVH, n = 29), or low-volume hospital (<10 cases/year, LVH, n = 158). Multivariable logistic regression and Cox-proportional hazards models were used to examine the effect of NCI-CCC status on treatment guideline adherence and ovarian cancer-specific survival. RESULTS: A total of 9,933 patients were identified (stage I, 22.8%; stage II, 7.9%; stage III, 45.1%; stage IV, 24.2%), and 8.1% of patients were treated at NCI-CCCs. Overall, 35.7% of patients received NCCN guideline adherent care, and NCI-CCC status (odds ratio [OR] 1.00) was an independent predictor of adherence to treatment guidelines compared with HVHs (OR 0.83, 95% CI 0.70 to 0.99) and LVHs (OR 0.56, 95% CI 0.47 to 0.67). The median ovarian cancer-specific survivals according to hospital type were: NCI-CCC 77.9 (95% CI 61.4 to 92.9) months, HVH 51.9 (95% CI 49.2 to 55.7) months, and LVH 43.4 (95% CI 39.9 to 47.2) months (p < 0.0001). National Cancer Institute Comprehensive Cancer Center status (hazard ratio [HR] 1.00) was a statistically significant and independent predictor of improved survival compared with HVH (HR 1.18, 95% CI 1.04 to 1.33) and LVH (HR 1.30, 95% CI 1.15 to 1.47). CONCLUSIONS: National Cancer Institute Comprehensive Cancer Center status is an independent predictor of adherence to ovarian cancer treatment guidelines and improved ovarian cancer-specific survival. These data validate NCI-CCC status as a structural health care characteristic correlated with superior ovarian cancer quality measure performance. Increased access to NCI-CCCs through regional concentration of care may be a mechanism to improve clinical outcomes.
Authors: Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown Journal: J Clin Oncol Date: 2005-11-21 Impact factor: 44.544
Authors: Robert J Morgan; Deborah K Armstrong; Ronald D Alvarez; Jamie N Bakkum-Gamez; Kian Behbakht; Lee-May Chen; Larry Copeland; Marta Ann Crispens; Maria DeRosa; Oliver Dorigo; David M Gershenson; Heidi J Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Sanja Percac-Lima; Mario Pineda; Steven C Plaxe; Matthew A Powell; Elena Ratner; Steven W Remmenga; Peter G Rose; Paul Sabbatini; Joseph T Santoso; Theresa L Werner; Jennifer Burns; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2016-09 Impact factor: 11.908
Authors: Deborah Schrag; Craig Earle; Feng Xu; Katherine S Panageas; K Robin Yabroff; Robert E Bristow; Edward L Trimble; Joan L Warren Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Robert E Bristow; Marianna L Zahurak; Teresa P Diaz-Montes; Robert L Giuntoli; Deborah K Armstrong Journal: Gynecol Oncol Date: 2009-09-18 Impact factor: 5.482
Authors: Barbara A Goff; Barbara J Matthews; Eric H Larson; C Holly A Andrilla; Michelle Wynn; Denise M Lishner; Laura-Mae Baldwin Journal: Cancer Date: 2007-05-15 Impact factor: 6.860
Authors: Jason D Wright; Yongmei Huang; Alexander Melamed; Ana I Tergas; Caryn M St Clair; June Y Hou; Fady Khoury-Collado; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Obstet Gynecol Date: 2019-06 Impact factor: 7.661
Authors: Renee A Cowan; Roisin E O'Cearbhaill; Ginger J Gardner; Douglas A Levine; Kara Long Roche; Yukio Sonoda; Oliver Zivanovic; William P Tew; Evis Sala; Yulia Lakhman; Hebert A Vargas Alvarez; Debra M Sarasohn; Svetlana Mironov; Nadeem R Abu-Rustum; Dennis S Chi Journal: Ann Surg Oncol Date: 2015-10-28 Impact factor: 5.344
Authors: Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson Journal: Gynecol Oncol Date: 2016-08-08 Impact factor: 5.482
Authors: Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson Journal: J Clin Oncol Date: 2016-08-08 Impact factor: 44.544